Actively Recruiting
Selinexor Combined with Temozolomide Compared to Temozolomide Alone for Recurrent Glioblastoma A Phase 1 and Randomized Phase 2 Trial
Led by National Cancer Institute (NCI) · Updated on 2026-10-23
97
Participants Needed
39
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, side effects, and best dose of selinexor combined with the usual chemotherapy drug temozolomide in patients with recurrent glioblastoma, a type of brain tumor that has returned after previous treatment. This trial includes a phase I dose-escalation study and a randomized phase II study comparing the combination treatment to temozolomide alone. Selinexor works by blocking a protein that may stop cancer cell growth, while temozolomide damages tumor cell DNA to slow or stop tumor growth. Participants receive temozolomide orally on days 1 to 5 of each 28-day cycle. In the combination group, selinexor is given orally on days 8 and 15, while the comparison group receives a placebo on those days. Cycles repeat every 28 days until disease progression or unacceptable side effects occur. Magnetic resonance imaging MRI and blood samples are collected during the study. After treatment ends, participants are followed up every 2 months for up to 2 years. During the study, participants undergo regular MRI scans and blood tests to monitor tumor response and health. Researchers measure progression-free survival, overall response rate, and overall survival, along with molecular markers that may predict response to selinexor. Safety and toxicity are closely tracked, especially during the phase I dose-finding part. The total participation time may last up to 3 years including follow-up assessments.
CONDITIONS
Brief Title
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here